Director Paul Schimmel's purchase of 317,999 shares signals insider confidence in aTyr Pharma, Inc. (NASDAQ:ATYR)'s future prospects.The company is currently involved in a class action lawsuit, which could affect investor sentiment and its reputation.aTyr's financials show challenges with a negative P/E ratio of -1.29 and a negative enterprise value to operating cash flow ratio of -1.60, but it maintains a low debt-to-equity ratio of 0.17 and a strong current ratio of 5.63.aTyr Pharma, Inc. (NASDAQ:ATYR) is ...